Companies › Jiangsu Simcere Pharmaceutical
17 active drug programs in 21 registered trials: 15 Phase 1, 6 Phase 3; Oncology, Other; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Trilaciclib Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor | CDK4, CDK6 | Phase 3 | Myelosuppression | Jul 2027 |
| Suvemcitug | – | Phase 3 | Refractory Metastatic Colorectal Cancer | Jan 2028 |
| Everolimus FK506-binding protein 1A inhibitor | FKBP1A | Phase 3 | Locally Advanced or Metastatic Breast Cancer | Aug 2028 |
| [14C] SIM0270 Selective estrogen receptor degrader (SERD) | ESR1 | Phase 3 | Locally Advanced or Metastatic Breast Cancer; Breast Cancer; Healthy Participants; Healthy Adult Participants | Aug 2028 |
| ENDOSTAR Recombinant human endostatin; antiangiogenic agent and vascular endothelial growth factor | VEGFA | Phase 3 | Malignant Pleural Effusion | – |
| SIM0237 | – | Phase 1 | Non-Muscle-Invasive Bladder Cancer (NMIBC) | Jan 2027 |
| SIM0388 Docetaxel polymeric micelle formulation (microtubule stabilizer) | Tubulin | Phase 1 | Malignant Ascites | Jun 2027 |
| SIM0508 | – | Phase 1 | Advanced Solid Tumors | Jun 2027 |
| SIM0500 | – | Phase 1 | Relapsed or Refractory Multiple Myeloma | Sep 2027 |
| SCR-6920 capsule PRMT5 inhibitor | PRMT5 | Phase 1 | Solid Tumor | Oct 2027 |
| SIM0610 | – | Phase 1 | Advanced Solid Tumours | Dec 2027 |
| SIM0686 | – | Phase 1 | Locally Advanced Solid Tumors | Dec 2027 |
| SIM0613 | – | Phase 1 | Advanced Solid Cancer | Jun 2028 |
| SIM0532 | – | Phase 1 | Histologically or Cytologically Confirmed Advanced Solid Tumors | Jun 2028 |
| SIM0609 | – | Phase 1 | Advanced Solid Cancer | Dec 2028 |
| SIM0689 for Injection PD-1/VEGF bispecific antibody | PDCD1, VEGFA | Phase 1 | Neoplasms, Malignant | Dec 2028 |
| SIM0811 | – | Phase 1 | Health, Subjective | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05293964 | [14C] SIM0270 | Phase 1 | Breast Cancer | Oncology | Dec 2024 |
| NCT04914598 | ENDOSTAR | Phase 3 | Malignant Pleural Effusion | Oncology | Feb 2025 |
| NCT04914598 | ENDOSTAR | Phase 3 | Malignant Pleural Effusion | Oncology | Feb 2025 |
| NCT06654791 | [14C] SIM0270 | Phase 1 | Healthy Participants | Other | Mar 2025 |
| NCT07345364 | SIM0811 | Phase 1 | Health, Subjective | Other | Jun 2026 |
| NCT07357610 | [14C] SIM0270 | Phase 1 | Healthy Adult Participants | Other | Oct 2026 |
| NCT06186414 | SIM0237 | Phase 1 | Non-Muscle-Invasive Bladder Cancer (NMIBC) | Oncology | Jan 2027 |
| NCT07007988 | SIM0388 | Phase 1 | Malignant Ascites | Oncology | Jun 2027 |
| NCT06686745 | SIM0508 | Phase 1 | Advanced Solid Tumors | Oncology | Jun 2027 |
| NCT07881705 | Trilaciclib | Phase 3 | Myelosuppression | Oncology | Jul 2027 |
| NCT06375044 | SIM0500 | Phase 1 | Relapsed or Refractory Multiple Myeloma | Oncology | Sep 2027 |
| NCT05528055 | SCR-6920 capsule | Phase 1 | Solid Tumor | Oncology | Oct 2027 |
| NCT07050459 | SIM0686 | Phase 1 | Locally Advanced Solid Tumors | Oncology | Dec 2027 |
| NCT07348211 | SIM0610 | Phase 1 | Advanced Solid Tumours | Oncology | Dec 2027 |
| NCT07361003 | Suvemcitug | Phase 3 | Refractory Metastatic Colorectal Cancer | Oncology | Jan 2028 |
| NCT07618260 | SIM0613 | Phase 1 | Advanced Solid Cancer | Oncology | Jun 2028 |
| NCT07749703 | SIM0532 | Phase 1 | Histologically or Cytologically Confirmed Advanced Solid Tumors | Oncology | Jun 2028 |
| NCT06680921 | Everolimus | Phase 3 | Locally Advanced or Metastatic Breast Cancer | Oncology | Aug 2028 |
| NCT06680921 | [14C] SIM0270 | Phase 3 | Locally Advanced or Metastatic Breast Cancer | Oncology | Aug 2028 |
| NCT07265921 | SIM0609 | Phase 1 | Advanced Solid Cancer | Oncology | Dec 2028 |
| NCT07660432 | SIM0689 for Injection | Phase 1 | Neoplasms, Malignant | Oncology | Dec 2028 |
Roche Pfizer AstraZeneca Akeso Shanghai Henlius Biotech Innovent Biologics (Suzhou) Jiangsu HengRui Medicine AbbVie Eli Lilly Amgen
Shanghai Hengrui Pharmaceutical Shandong Suncadia Medicine Sichuan Kelun-Biotech Biopharmaceutical Mabwell (Shanghai) Bioscience Akeso
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.